Pharmaceutical Company - Publications - Faculty & Research - Harvard Business School

Filter Results: (422)

Filter Results: (422)

Show Results For

← Page 4 of 422 Results →

Sort by

Are you looking for?

→Search All HBS Web

26 Apr 2023
Cold Call Podcast

How Martine Rothblatt Started a Company to Save Her Daughter

Keywords: Re: Debora L. Spar; Pharmaceutical; Pharmaceutical; Pharmaceutical

November 2016
Case

QuintilesIMS: Biosimilar Marketing in England

By: John A. Quelch and Emily C. Boudreau

QuintilesIMS was a leading healthcare consulting firm best known for its data and information offerings as well as its market research and management consulting services for life science companies. By 2015, the company was expanding beyond the biopharmaceutical... View Details

Keywords: Health; Pharmaceutical Industry; Biotech; Marketing; Health Care and Treatment; Biotechnology Industry; England

October 2022 (Revised September 2024)
Case

mPharma: Scaling Access to Affordable Primary Care in Africa

By: Regina E. Herzlinger and Ben Creo

mPharma hopes to scale up to create the largest pan-African healthcare company ever to provide much-needed primary care in retail pharmacies; a reliable, fairly priced supply of drugs; and micro-insurance for drugs. They must prioritize launching a telemedicine... View Details

October 2014 (Revised May 2017)
Teaching Note

Pfizer and AstraZeneca: Marketing an Acquisition (A) & (B)

By: John A. Quelch

Keywords: Mergers ＆ Acquisitions; Pharmaceutical Companies; Economic Impact Of Mergers; Mergers Impact On International Economies; Impact On Consumers Of Mergers; Customers; Economics; Marketing; Planning; Strategy; Pharmaceutical Industry; Europe; North and Central America

February 2015 (Revised November 2015)
Case

Building an Integrated Biopharma Company: Crucell (A)

By: Richard G. Hamermesh, Marianne Van Der Steen and Susan S. Harmeling

By 2009, Crucell had become the largest biopharma company in the Netherlands and a symbol of national pride. The case traces the evolution of the company from a University spin-off into a fully-integrated company. Crucell's success, particularly in the vaccine space,... View Details

Keywords: Biotechnology; Biopharmacy Company; Licensing; Licensing Agreements In Biopharmacy; Human Cell-line Technology; Vaccine; Healthcare Innovation; Global Health; Partners and Partnerships; Entrepreneurship; Growth and Development Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Netherlands

March 2014
Case

Novartis' Sandoz: Between Generics and Pharma

By: Krishna Palepu and Carin-Isabel Knoop

Sandoz, which made a significant investment in bio-similars as a way to differentiate itself from its generic drug industry peers, has to negotiate with its parent company and the innovative pharma division on how best to commercialize its bio-similar portfolio. What... View Details

Keywords: Global Strategy And Leadership; Managing Within A Multi-Business Organization; Generic Pharmaceuticals; Global Strategy

November 2013
Case

GlaxoSmithKline in China (A)

By: John A. Quelch and Margaret L. Rodriguez

Four GlaxoSmithKline employees were accused of bribing Chinese health care workers to prescribe the company's drugs. The accusations brought to light the questionable incentive structures of the Chinese health care system and the pressure on companies to adhere to... View Details

November 2013 (Revised September 2015)
Supplement

GlaxoSmithKline in China (B)

By: John A. Quelch and Margaret L. Rodriguez

In 2013, Chinese investigators detained four GSK employees for allegedly bribing health care staff to sell GSK pharmaceuticals. A month later, GSK's Asia Pacific regional president, Abbas Hussain, said the company would help identify corrupt practices. Two days later,... View Details

February 2016 (Revised March 2022)
Case

Express Scripts: Promoting Prescription Drug Home Delivery (B)

By: John Beshears, Patrick Rooney and Jenny Sanford

The pharmacy benefit manager (PBM) sector processes prescription drug claims on behalf of companies that offer a prescription drug benefit to their employees. This case follows Bob Nease, Chief Scientist at Express Scripts, as he considers methods to promote home... View Details

Keywords: Pharmaceuticals; Prescription Drugs; Pharmacy Benefit Manager; PBM; Healthcare; Behavioral Economics; Choice Architecture; Active Choice; Health Care and Treatment; Service Delivery; Decision Choices and Conditions; Order Taking and Fulfillment; Compensation and Benefits

March 2016 (Revised March 2022)
Teaching Note

Express Scripts: Promoting Prescription Drug Home Delivery (A) and (B)

By: John Beshears

The pharmacy benefit manager (PBM) sector processes prescription drug claims on behalf of companies that offer a prescription drug benefit to their employees. The case associated with this teaching note follows Bob Nease, chief scientist at Express Scripts, as he... View Details

Keywords: Pharmaceuticals; Prescription Drugs; Pharmacy Benefit Manager; PBM; Healthcare; Behavioral Economics; Choice Architecture; Active Choice; Service Delivery; Decision Choices and Conditions; Consumer Behavior; Distribution Channels; Health Care and Treatment; Pharmaceutical Industry; Pharmaceutical Industry

February 2016
Case

Express Scripts: Promoting Prescription Drug Home Delivery (A)

By: John Beshears, Patrick Rooney and Jenny Sanford

The pharmacy benefit manager (PBM) sector processes prescription drug claims on behalf of companies that offer a prescription drug benefit to their employees. This case follows Bob Nease, Chief Scientist at Express Scripts, as he considers methods to promote home... View Details

Keywords: Pharmaceuticals; Prescription Drugs; Pharmacy Benefit Manager; PBM; Healthcare; Behavioral Economics; Choice Architecture; Active Choice; Service Delivery; Decision Choices and Conditions; Health Care and Treatment; Order Taking and Fulfillment; Compensation and Benefits; Pharmaceutical Industry

12 Jun 2018
Research & Ideas

In a Landscape of 'Me Too' Drug Development, What Spurs Radical Innovation?

ubingruo New research finds that large pharmaceutical companies, typically conservative in their pursuit of novel drug development, are more willing to undertake radical innovation after receiving an unexpected cash windfall. The View Details

Keywords: by Rachel Layne; Pharmaceutical; Pharmaceutical

June 2003 (Revised May 2006)
Case

Cipla

By: Rohit Deshpande and Laura Winig

The head of Cipla, a $325-million-dollar Indian pharmaceutical company and seller of low-cost AIDS drugs to South Africa, must decide what to do about Cipla's future. With India poised to enforce international patents in only two years, much of Cipla's product line... View Details

Keywords: Trade; Price; Global Strategy; Health Care and Treatment; Patents; Leadership; Marketing Strategy; Health Industry; South Africa; India

June 1996 (Revised February 1998)
Case

Repositioning Ranbaxy

A leading Indian pharmaceutical company reacts to changes in its industry by trying to reposition along several dimensions from developing markets to developed ones, from bulk drugs toward pharmaceuticals in dosage forms, and from reverse-engineering products developed... View Details

Keywords: Organizational Change and Adaptation; Expansion; Industry Structures; Pharmaceutical Industry; India

April 2009 (Revised April 2009)
Case

Immusol and Novartis

By: Regina E. Herzlinger, Keyne M. Monson, Juan D. Betancourt and Victor Li

Should Immusol strive to become a fully integrated pharmaceutical company? How should a small pharmaceutical company structure a deal for its novel technology with the giant Novartis? View Details

Keywords: Technological Innovation; Rights; Negotiation Deal; Negotiation Participants; Alliances; Pharmaceutical Industry

September 2019
Case

Celgene: Business Development and Distributed Research

By: Peter Barrett and Kareem Reda

This case looks at the deal-making process between Celgene, a large publicly traded pharmaceutical company, and Agios, an early-stage biotech company. The framework of a potential deal is explored and the potential road-blocks to Agios’ profitability are discussed. ... View Details

Keywords: Negotiation Deal; Alliances; Collaborative Innovation and Invention; Research; Pharmaceutical Industry; Pharmaceutical Industry

October 1993 (Revised February 1995)
Case

Dendrite International

By: Frank V. Cespedes and Marie Bell

Dendrite International is a $23 million (1992 revenues) supplier of sales automation software to pharmaceuticals companies in Europe, Japan, and the United States. The firm's strategy has depended on being a full-service supplier to multinational firms. Impending... View Details

Keywords: Accounting Audits; Cost vs Benefits; Forecasting and Prediction; Marketing Strategy; Risk and Uncertainty; Sales; Competitive Advantage; Information Technology Industry; Japan; Europe; United States

August 1990 (Revised January 1992)
Case

Eli Lilly and Co. (B): Europe

By: Michael Y. Yoshino

Examines the challenges facing the company in light of the changing economic, regulatory, and competitive environment in the European pharmaceutical industry. Examines the steps taken by the company adapting to this changing situation as part of a total globalization... View Details

Keywords: Change Management; Economics; Global Strategy; Business or Company Management; Growth and Development Strategy; Adaptation; Competition; Pharmaceutical Industry; Europe

December 2007 (Revised May 2009)
Case

Can PACIV (Puerto Rico) Serve European Customers?

Jorge Rodriguez-Gonzalez, PACIV's (Puerto Rico) founding CEO, is considering expanding PACIV's pharmaceutical manufacturing compliance services company to the U.K. and Europe. He has to decide whether to hire Wayne Snelgrove and how to define the scope of his... View Details

Keywords: Customer Focus and Relationships; Entrepreneurship; Cross-Cultural and Cross-Border Issues; Global Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Europe; United Kingdom; Puerto Rico

August 2023 (Revised May 2024)
Case

Dicerna Pharmaceuticals: Decision Making in Clinical Trial Design and Operations

By: Satish Tadikonda and Amanda McEwen

The success or failure of Dicerna Pharmaceuticals (Dicerna) as an emerging pharmaceutical company would likely hinge on its lead drug candidate Nedosiran and the company’s ability to see it successfully through clinical development. Ralf Rosskamp, Chief Medical... View Details

Keywords: Business Strategy; Health Testing and Trials; Product Development; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry

←
4
5
…
21
22
→